White Matter Lesion Volumes on 3‐T MRI in People With MS Who Had Followed a Diet and Lifestyle Program for More Than 10 Years
Authors:
- Mariaan JafthaMJMariaan Jaftha
- Frances RobertsonFRFrances Robertson
- Susan J. van RensburgSRSusan J. van Rensburg
- Ronald van ToornRTRonald van Toorn
- Merlisa C. KempMKMerlisa C. Kemp
- Clint JohannesCJClint Johannes
- Kelebogile E. MoremiKMKelebogile E. Moremi
- Maritha J. KotzeMKMaritha J. Kotze
- Penelope Engel-HillsPEPenelope Engel-Hills
Open Access
- 1 January 2024
- journal article
- research article
- Published by Wiley in Multiple Sclerosis International
- Vol. 2024 (1) , 8818934
Abstract
Background: Cerebral white matter lesion (WML) formation in people with multiple sclerosis (pwMS) is linked to the death of myelin‐producing oligodendrocytes. Current MS treatment strategies focus on limiting WML accumulation and disability. Using a pathology‐supported genetic testing (PSGT) program, we identified specific risk factors for MS, categorized as deficiencies and aggravators. We developed a novel clinical methodology to mitigate these risk factors, including personalized lifestyle interventions and optimization of cerebral nutrients to prevent oligodendrocyte demise and promote remyelination.Objective: To conduct a pilot case‐control study over a 10‐year period to ascertain whether the PSGT Program can reduce or prevent WML formation in pwMS.Methods: MRI was performed at baseline as well as after an interval period of at least 10 years or longer in 22 pwMS. WML volumes were determined using Sequence Adaptive Multimodal SEGmentation (SAMSEG) software, part of FreeSurfer 7.2. Other variables included age at MRI, disease duration, disability status, and medication.Results: PwMS (n = 13) who had followed the PSGT program for more than 10 years, had significantly smaller lesion volumes (mm3) compared to pwMS who did not adhere to the program (n = 9) (4950 ± 5303 vs. 17934 ± 11139; p = 0.002). WML volumes were significantly associated (p = 0.02) with disability (EDSS) but not with age (p = 0.350), disease duration (p = 0.709), or Interferon‐β treatment (p = 0.70).Conclusion: Dietary and lifestyle changes may lower the risk of developing cerebral WMLs in pwMS and potentially slow disease progression. Larger studies are required to confirm the effectiveness of such interventions in pwMS.Keywords
All Related Versions
Funding Information
- Cape Peninsula University of Technology
- National Health Laboratory Service (94139)
This publication has 53 references indexed in Scilit:
- World Medical Association Declaration of HelsinkiJAMA, 2013
- The conundrum of iron in multiple sclerosis – time for an individualised approachMetabolic Brain Disease, 2012
- Oxidative stress disrupts oligodendrocyte maturationJournal of Neuroscience Research, 2009
- Lack of clinical manifestation of hereditary haemochromatosis in South African patients with multiple sclerosisMetabolic Brain Disease, 2006
- Iron and the folate-vitamin B12-methylation pathway in multiple sclerosisMetabolic Brain Disease, 2006
- Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesionAnnals of Neurology, 2004
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 2001
- Multiple sclerosis, porphyria-like symptoms, and a history of iron deficiency anemia in a family of Scottish descentAmerican Journal of Medical Genetics, 1999
- Relationship of iron to oligondendrocytes and myelinationGlia, 1996
- Biochemical pathogenesis of subacute combined degeneration of the spinal cord and brainJournal of Inherited Metabolic Disease, 1993